CVE-2026-28511elabftw has entry title leakage through autocompletion search
Updated under an hour ago ()
Does this affect you?
It affects elabftw. Add what you run to find out whether that includes you.
No exploitation reported and no EPSS estimate yet.
Do this next
Free account, 1 product
eLabFTW is an open source electronic lab notebook. Prior to version 5.4.2, in certain cases, an authenticated user performing a numeric reference/search can return results that include resources the requesting user is not authorized to view. The exposed information is limited (only the title). Attempts to access the underlying protected resource content remain blocked by authorization checks. Version 5.4.2 fixes the issue. # Affected Scope Cross-scope visibility of titles. No confirmed bypass of content-level access controls # Preconditions An authenticated user account No special privileges required beyond standard access # Impact This may enable unauthorized disclosure of sensitive information if confidential data is included in resource titles. Examples could include project names, patient identifiers, or other regulated information embedded in titles.
- CVSS
- 4.3 MEDIUM (v3.1, CNA)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
- Weakness (CWE)
- CWE-200
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- GitHub_M
- NVD analysis
- Analyzed
- Record last updated
- Jun 2, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
elabftw elabftw elabftw:elabftw (from the name) | before 5.4.2 | CNA record |
elabftw elabftw elabftw:elabftw | before 5.4.2 | NVD |
References
- https://github.com/elabftw/elabftw/security/advisories/GHSA-wm4r-p2jg-2mj3x-refsource-confirm, vendor-advisory
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.